M. Shing

P201 Subcutaneous versus intravenous trastuzumab in early breast cancer: 2-year follow-up of HannaH

P201 Subcutaneous versus intravenous trastuzumab in early breast cancer: 2-year follow-up of HannaH C. Jackisch *, R. Hegg, D. Stroyakovskiy, J. Ahn, B. Melichar, S.C. Chen, A. Crepelle-Flechais, D. Heinzmann, M. Shing, X. Pivot. Department of Obstetrics and Gynecology & Breast Cancer and Gynecology Cancer Center, Sana Klinikum Offenbach GmbH, Offenbach, Germany, Department of Gynecology and Obstetrics, Hospital Perola Byington, Sao Paulo, Brazil, Chemotherapeutic Department, City Clinical Oncology Hospital 62, Moscow, Russian Federation, Department of Medicine, Samsung Medical Center, Seoul, Korea, Department of Oncology, Palacký University Medical School & Teaching Hospital, Olomouc, Czech Republic, Department of Surgery, Chang Gung Memorial Hospital, Taipei, Taiwan, Global Pharma Development, F. Hoffmann-La Roche Ltd, Basel, Switzerland, Biostatistics, F. Hoffmann-La Roche Ltd, Basel, Switzerland, Global Pharma Development, Genentech, Inc., South San Francisco, United States of America, Chemotherapy–Oncology, CHU Jean Minjoz, Besancon, France

Adjuvant Subcutaneous Trastuzumab for HER2‐Positive Early Breast Cancer: Subgroup Analyses of Safety and Active Medical Conditions by Body Weight in the SafeHer Phase III Study

BACKGROUND This SafeHer subgroup analysis assessed the safety of fixed-dose subcutaneous trastuzumab (H SC) as an adjuvant therapy in HER2-positive early breast cancer (EBC) by body weight. PATIENTS AND METHODS Patients with HER2-positive EBC not previously treated with anti-HER2 therapy received H SC 600 mg (every 3 weeks for 18 cycles), with neoadjuvant or adjuvant chemotherapy or without adjuvant chemotherapy. Adverse events (AEs) were assessed throughout treatment and at final follow-up (28 ±5 days after last treatment). Subgroups were categorized by body weight, Asian origin, and chemotherapy administration. All analyses were descriptive. RESULTS Of 2,577 patients enrolled, 2,573 received ≥1 dose of study medication and were included in this safety analysis. Median body weight at baseline was 67.0 kg (range 33.6-150.0 kg). Any-grade AEs occurred in 88.7% (2,282/2,573) of the overall population, versus 87.1% (590/677) of the lowest bodyweight quartile (≤59 kg), 90.0% (561/623) of the highest quartile (>77 kg), and 86.5% (327/378) of the Asian population. Grade ≥3 AEs occurred in 23.2% (596/2,573) of the overall population, 17.9% (121/677) of the lowest bodyweight quartile, 26.8% (167/623) of the highest quartile, and 15.3% (58/378) of the Asian population. The highest bodyweight quartile had the highest incidence of medical conditions at baseline (highest quartile, 75.6%; lowest quartile, 56.1%). CONCLUSION These data support the use of fixed-dose H SC as an adjuvant therapy in HER2-positive EBC and confirm the comparable safety profile of H SC in patients with low body weight or of Asian origin versus the overall population in SafeHer. ClinicalTrials.gov: NCT01566721. IMPLICATIONS FOR PRACTICE The safety profile of fixed-dose subcutaneous trastuzumab (H SC) was comparable between patients in the lowest bodyweight subgroup and the overall patient population, and also between patients of Asian origin (of whom a higher proportion often fall within the lower bodyweight quartiles) and the overall population. The safety data from this SafeHer subgroup analysis therefore support the use of fixed-dose H SC 600 mg administered every 3 weeks as an adjuvant therapy for patients with HER2-positive early breast cancer across different bodyweight subgroups and in the Asian patient population.